OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.810
-0.060 (-2.09%)
At close: May 12, 2025, 4:00 PM
2.850
+0.040 (1.42%)
After-hours: May 12, 2025, 7:29 PM EDT
OncoCyte Revenue
In the year 2024, OncoCyte had annual revenue of $1.88M with 25.15% growth. OncoCyte had revenue of $1.49M in the quarter ending December 31, 2024, with 373.25% growth.
Revenue (ttm)
$1.88M
Revenue Growth
+25.15%
P/S Ratio
19.94
Revenue / Employee
$38,388
Employees
49
Market Cap
80.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
OCX News
- 4 hours ago - OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - Oncocyte Reports Q1 2025 Results and Business Progress - GlobeNewsWire
- 5 days ago - Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - GlobeNewsWire
- 12 days ago - Oncocyte Provides Positive Update on Clinical Trial Progress - GlobeNewsWire
- 13 days ago - Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - GlobeNewsWire
- 7 weeks ago - OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - GlobeNewsWire
- 3 months ago - Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - GlobeNewsWire